Dianthus Therapeutics vs Neuphoria Therapeutics
DNTH and NEUP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DNTH and NEUP compare
Dianthus Therapeutics scores higher on the StockData Score (7 against 5 for Neuphoria Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DNTH | NEUP |
|---|---|---|
| Size and price | ||
| Market cap | $5.1B | – |
| Share price | $91.81 | $2.55 |
| Change, 1 year | 137% | −48.0% |
| Change, 5 years | −14.2% | – |
| Beta (5Y) | 1.44 | 0.86 |
| Employees | 92 | 7 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 4.1× | – |
| Profitability | ||
| Return on equity | −22.6% (better) | −61.7% |
| Return on invested capital | −22.2% (better) | −273% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 30.02 (better) | 27.85 |
| Altman Z-score | 88.13 | – |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | −0.01% | – |
| Shareholder yield | −0.01% | – |
| Ownership | ||
| Held by institutions | 118% | 36.8% |
| Held by insiders | 9.1% | – |
| Insider net buying, 12 months | −$75.1M | $0 (better) |
| Short interest, % of float | 18.2% | – |
Go deeper
- DNTH stock overview
- DNTH income statement
- DNTH valuation and score
- NEUP stock overview
- NEUP income statement
- NEUP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.